Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: A pooled and comparative analysis of data from USA and European Union clinical trials

Blood Transfusion

Volumn 11, Issue 4, 2013, Pages 533-540

  Mannucci, Pier O ^a   Kyrle, Paul Alexander ^b   Schulman, Sam ^c   Di Paola, Jorge ^d   Schneppenheim, Reinhard ^e   Gill, Joan Cox ^f  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Elective surgery; Factor VIII; Prophylaxis; Von Willebrand's disease

Indexed keywords

BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD CLOTTING; BRAIN HEMORRHAGE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ELECTIVE SURGERY; EPISTAXIS; EUROPEAN UNION; FEMALE; FEVER; HEADACHE; HEMOSTASIS; HUMAN; IN VIVO STUDY; INJECTION SITE BLEEDING; LOADING DRUG DOSE; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PAIN; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PROPHYLAXIS; SINGLE BLIND PROCEDURE; STUDY DESIGN; SUBDURAL HEMATOMA; TREATMENT DURATION; UNITED STATES; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FACTOR VIII; FEMALE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84891931494     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0254-12     Document Type: Article

References (22)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
2. Thompson AR, Gill JC, Ewenstein BM, et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004; 10: 42-51.
3. Zimmerman TS, Ruggeri ZM. von Willebrand's disease. Clin Haematol 1983; 12: 175-200.
4. Blanchette V, Israels SJ, Akabutu J, Bergman GE. Report of the efficacy and safety of Haemete P in Canadian von Willebrand disease (vWD) patients. Thromb Haemost 1997; 77: 513.
5. Ewenstein BM, Gill JC, Thompson A. Treatment of von Willebrand disease (vWD) in patients with urgent life-or-limb-threatening bleeding or emergent surgery with Humate-P (factor VII/vWF concentrate). Haemophilia 2000; 6: 277.
6. Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica 2007; 92: 944-51.
7. Franchini M. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage. Blood Transfus 2008; 6 (Suppl 2): s33-8.
8. Gill JC, Shapiro A, Valentino LA, et al. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. Haemophilia 2011; 17: 895-905.
9. Lethagen S, Kyrle PA, Castaman G, et al. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-30.
10. Lillicrap D, Poon MC, Walker I, et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-30.
11. Lubetsky A, Schulman S, Varon D, et al. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thromb Haemost 1999; 81: 229-33.
12. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16 (Suppl 1): S17-21.
13. Alusi GH, Grant WE, Lee CA, et al. Bleeding after tonsillectomy in severe von Willebrand's disease. J Laryngol Otol 1995; 109: 437-9.
14. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4 (Suppl 3): 33-9.
15. Lethagen S. Haemostatic treatment in connection with surgery in patients with von Willebrand disease. Haemophilia 1999; 5: 64-7.
16. Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001; 66: 280-4.
17. Franchini M, Rossetti G, Tagliaferri A, et al. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003; 88: 1279-83.
18. Michiels JJ, Berneman ZN, van der Planken M, et al. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). Blood Coagul Fibrinolysis 2004; 15: 323-30.
19. Naqvi A, Endres-Brooks J, Montgomery RR. Successful cardiac surgery in a young girl with type 2a von Willebrand disease using continous infusions of Haemete-P. Thromb Haemost 1997; 77: 514.
20. Di Paola J, Lethagen S, Gill J, et al. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery. Haemophilia 2011; 17: 752-8.
21. Gill JC, Ewenstein BM, Thompson AR, et al. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003; 9: 688-95.
22. CSL Behring LLC. Humate-P dosing calculator. Available at: http://www.humate-p.com/Professional/Resources-and-Tools/Dosage-Calculator.aspx. Accessed on 26 October 2012.